Drugs / FB301
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07453069 | Jul → Oct 2026 expected | — | Freya Biosciences ApS | Recruiting | No outcome recorded |
| Phase 2 | NCT07481955 | Mar 2026 → Mar 2027 expected | bacterial vaginosis | Freya Biosciences ApS | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-04-16 | Freya Biosciences ApS | Results Freya Biosciences announces positive Phase 1 first-in-human data with FB301 for IVF-related embryo implantation failure freyabiosciences.com ↗
The study met all primary and secondary endpoints, demonstrating that FB301 was safe and well tolerated across all cohorts, with no serious adverse events (SAEs), severe adverse events, or discontinuations reported. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-04-16 | Freya Biosciences ApS | Freya Biosciences announces positive Phase 1 first-in-human data with FB301 for IVF-related embryo implantation failure freyabiosciences.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FB301 | “The goal of this study is to evaluate how treatment with FB301 affects the balance of vaginal bacteria in women (aged 18-45) with bacterial vaginosis after pre-treatment with...” NCT07481955 ↗ |
| Modality | Other / unclassified | “FB301, a Live Biotherapeutic Product (LBP) comprising consortia of Lactobacillus strains” NCT07481955 ↗ |
| Route | Other | “intravaginal FB301” NCT07481955 ↗ |